Information for prescription drug manufacturers
Important: User guide updates July 2023 include information about new iReg filing statuses.
Prescription drug manufacturers that meet the definition of a reporting manufacturer are required to register with the Drug Price Transparency Program and pay an annual assessment to cover program expenses. Some companies have multiple entities in their organization that meet this definition so each entity must be registered and pay the annual assessment. Reporting manufacturers pay an annual fee currently due Oct. 1. An entity is a reporting manufacturer, if it meets all of the following:
- Required to register with the Oregon Board of Pharmacy as a drug manufacturer
- Manufactures prescription drugs sold in this state as defined by ORS 646A.689(1)(d)
- Sets or changes the wholesale acquisition cost (WAC) of those drugs
iReg system access:
iReg is Oregon's system for manufacturers to submit reports, view correspondence, provide additional reporting information, and view assessments. An iReg account is created when a reporting manufacturer is initially registered with the program.
Due to the large number of companies registered with the program, we ask that manufacturers manage access for users whenever possible. Every company should have at least one registered user with the appropriate permissions to manage users on the manufacturer's account. There should be at least one person who is a user and one person who is a contact, with at least two different people in the company as users or contacts. A user is someone who can view the account information in iReg, submit reports, and view billing information. A contact is someone who receives notices, such as when we send correspondence. It is important to mark all the boxes to receive all types of notices. The company is responsible for keeping current both your user and contact information.
Find instructions on user management in our
Manufacturer User Guide. If you have questions or need help, email firstname.lastname@example.org.
iReg reporting system
Submitting drug reports
All reporting manufacturers are required to report on prescription drug price increases and on new prescription drugs that meet the threshold reporting requirements. Do not submit reports that are not required. After reviewing the user guide, let us know if you have questions about whether to submit and what information is required. You can email us at
Manufacturer User Guide is meant to help reporting manufacturers comply with the requirements in ORS 646A.680 through 646A.692 and OAR 836-200-0500 through OAR 836-200-0560 for Oregon's Drug Price Transparency Program.
New drug reporting:
- A report is required, within 30 days of introduction, for each prescription drug National Drug Code (NDC) for sale in the U.S. when the price of the NDC exceeds the threshold set by the Centers for Medicare and Medicaid Services in Medicare Part D for a 30-day supply or for a course of treatment lasting less than one month. The threshold was set when the program began and is $670 per OAR 836-200-0505.
Annual price increase reporting:
ATTENTION: Annual price increase reporting is currently in the process of complying with the recent court ruling and system updates are in progress. The system is not yet ready to process revised filings as indicated in DFR Bulletin No. 2024-3 and the ability to create and submit reports has been disabled. We will send a notice once the system is ready. The due date for the revised filings has been extended to May 15, 2024.
A report is required by
March 15 for each NDC when both of the following criteria are met:
- The average price for the calendar year that just ended is compared to the average price for the previous calendar year and the price has increased by 10 percent or more. Here, average price means the weighted average of the WAC prices of the drug package from the calendar year, with each price weighted according to how many days it was in effect. See the user guide for more information.
- The price at any point during the calendar year that just ended was $100 or more for a one-month supply, or for a course of treatment lasting less than one month.
Example 1: A package of Drug A contains a three-month supply of the drug; the average price of the package was $700 for 2020, and the average price was $850 for 2021. The price for a one-month supply of Drug A was higher than $100 in 2021, and the increase of the average price comparing the two years is greater than 10 percent, so a report was filed for Drug A by March 15, 2022, to report the 2021 price increase.
Sixty-day notice price increase reporting:
- A report is required 60 days before a price increase for each NDC for a brand-name prescription drug when the planned price increase is 10 percent or more OR the increase is $10,000 or more.
Example 2: A brand-name prescription drug's WAC is currently $500 and there is a plan to increase it to $600. This increase is more than 10 percent, so a report is filed at least 60 days before that price increase.
- A report is required 60 days before a price increase for each NDC for a generic prescription drug when the planned price increase is 25 percent or more AND the increase is $300 or more.
Example 3: A generic prescription drug's WAC is currently $200 and there is a plan to increase it to $300. This increase is more than 25 percent, but the increase is less than $300, so a report is not filed.
- There are more examples and information on the report filing requirements in Bulletin No. 2020-12.
Exceptions: No report is required if the prescription drug is manufactured by four or more companies and meets one of the criteria listed in ORS 646A.683(4).
We use Biscom to securely communicate information claimed as trade secret. We will generally send access instructions to the user who submitted the report with claimed trade secrets. If we send communication in Biscom, we will also add a message in iReg. Those listed as contacts for a manufacturer are automatically notified when a message is posted in iReg if they have all required notices selected on their contact profile. It is important that both users and contacts are up to date and the correct people are receiving the notices. A manufacturer only needs access to Biscom if we issue a trade secret determination. Here are instructions about using Biscom, but remember that Biscom is only used to receive a trade secret determination and you will not reply to us using Biscom: external user guide
Billings and collections
Manufacturers currently owe an assessment on Oct. 1 each year. The demand to pay notice and reminders are sent by email to the contacts on the account in iReg. View the billing status, details, and fiscal details in iReg.
You can download our Form W-9, if needed. Here is our mailing and physical address for sending payments:
Oregon Dept. of Consumer & Business Services
Central Services Division
P.O. Box 14610
Salem, OR 97309-0445
Oregon Dept. of Consumer & Business Services
Central Services Division
350 Winter St. NE
Salem, OR 97301-3883
Refer to “Assessment and collections" in our Manufacturer User Guide. Manufacturer accounts with unpaid billings sent to collections will show a banner message in iReg that says “In Collections" on the blue bar near the top of the page.
Manufacturer guidance webinar,
Feb. 16, 2023